Epoch Investment Partners Inc. purchased a new position in Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,134,243 shares of the company's stock, valued at approximately $66,916,000. Epoch Investment Partners Inc. owned about 0.16% of Kenvue as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the stock. Grove Bank & Trust increased its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in Kenvue in the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. raised its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Citigroup raised their target price on shares of Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Barclays reduced their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, April 14th. Finally, UBS Group dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $24.42.
Check Out Our Latest Research Report on KVUE
Kenvue Stock Down 0.2 %
KVUE traded down $0.04 during trading on Friday, reaching $22.71. 4,071,787 shares of the stock were exchanged, compared to its average volume of 17,029,849. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock's 50 day moving average price is $23.01 and its two-hundred day moving average price is $22.42. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $43.58 billion, a P/E ratio of 42.80, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.61%. Kenvue's dividend payout ratio is currently 154.72%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
